July 28, 2022
Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases
3rd B&T Cell-Mediated Autoimmune Disease Drug Development
Read More
June 26, 2022
Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology
37th ACS National Medicinal Chemistry Symposium
MYD88 Tumors
Read More
June 7, 2022
Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications
Targeting protein degradation 3 – from discovery to the clinic (TPD3)
MYD88 Tumors
Read More
June 6, 2022
Discovery and targeted mass spectrometry-based proteomics: Enabling technologies advancing IRAK4 protein degrader along the drug discovery pipeline into the clinic
The American Society for Mass Spectrometry (ASMS) Annual Conference
Read More
June 1, 2022
Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
MYD88 Tumors
Read More
June 1, 2022
Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
CTCL
LGL-L
PTCL
Solid Tumors
Read More
May 31, 2022
STAT3 degraders inhibit Th17 development and cytokine production resulting in profound inhibition of collagen-induced autoimmune murine arthritis
European Alliance of Associations for Rheumatology (EULAR) 2022 Annual Congress
Read More
May 17, 2022
Kinetics of IRAK4 Degradation and Impact on Functional Response in Circulating Immune Cells and Skin Cell Subsets
Society for Investigative Dermatology (SID) 2022 Annual Meeting
Read More
May 10, 2022
Non-Clinical Safety Considerations when Developing Targeted Protein Degraders
Applied Pharmaceutical Toxicology (APT) 2022
Read More
May 3, 2022
Selective IRAK4 Degradation, Not Kinase Inhibition, Blocks TLR-activated NF-kB and p38 Signaling Leading to broad Cytokine Inhibition
The American Association of Immunologists (AAI) Immunology2022(TM)
Read More